Published in J Clin Invest on March 14, 2011
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood (2013) 1.67
Immune Modulation in Hematologic Malignancies. Semin Oncol (2015) 0.92
Immunological off-target effects of imatinib. Nat Rev Clin Oncol (2016) 0.81
Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood (2012) 0.80
Understanding anti-leukemia responses to donor lymphocyte infusion. Oncoimmunology (2014) 0.79
Expression levels of cytokines and chemokines increase in human peripheral blood mononuclear cells stimulated by activation of the Toll-like receptor 5 pathway. Exp Ther Med (2015) 0.78
The stimulatory activity of plasma in patients with advanced non-small cell lung cancer requires TLR-stimulating nucleic acid immunoglobulin complexes and discriminates responsiveness to chemotherapy. Cancer Cell Int (2014) 0.75
Sensing danger: toll-like receptors and outcome in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2016) 0.75
Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 19.15
Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol (2008) 15.90
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04
TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol (2004) 8.06
Control of B-cell responses by Toll-like receptors. Nature (2005) 6.44
Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science (2009) 6.07
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 6.00
Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol (2006) 6.00
The plasticity of dendritic cell responses to pathogens and their components. Science (2001) 5.58
RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med (2005) 4.85
Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res (1977) 4.59
RNA recognition and signal transduction by RIG-I-like receptors. Immunol Rev (2009) 4.41
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest (2005) 3.93
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 3.50
Toll-dependent control mechanisms of CD4 T cell activation. Immunity (2004) 2.88
BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med (2007) 2.70
Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev (1999) 2.21
TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells. Eur J Immunol (2007) 2.15
A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol (2003) 2.04
T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity (2008) 2.03
Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas (1998) 2.03
Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol (2008) 1.89
RNA-based viral immunity initiated by the Dicer family of host immune receptors. Immunol Rev (2009) 1.82
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood (2008) 1.82
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood (1998) 1.52
JColorGrid: software for the visualization of biological measurements. BMC Bioinformatics (2006) 1.43
Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest (2000) 1.41
Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol (2006) 1.35
CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol (2004) 1.32
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2001) 1.30
Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett (1995) 1.28
Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol (2003) 1.26
CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol (2002) 1.23
Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum (2008) 1.20
Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res (2008) 1.16
Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant (2007) 1.16
Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet Immunol Immunopathol (2008) 1.13
TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha. Int Immunopharmacol (2007) 1.09
Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res (2010) 1.09
Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br J Haematol (2007) 1.09
Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res (2010) 1.08
Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res (2010) 1.04
The host environment regulates the function of CD8+ graft-versus-host-reactive effector cells. J Immunol (2008) 1.01
Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. Int J Cancer (2010) 0.96
Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood (2007) 0.96
Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res (2005) 0.93
Intracellular DNA sensors in immunity. Curr Opin Immunol (2008) 0.92
RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells. Cancer Lett (2008) 0.90
Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother (2008) 0.90
Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother (2004) 0.88
TLR ligands differentially modulate T cell responses to acute and chronic antigen presentation. J Immunol (2007) 0.86
Observations on the role of endotoxin in graft-versus-host disease. Prog Clin Biol Res (1988) 0.84
In vivo adjuvant activity of the RNA component of the Sm/RNP lupus autoantigen. Arthritis Rheum (2007) 0.83
CpG motifs to modulate innate and adaptive immune responses. Int Rev Immunol (2006) 0.78
Full-length transcriptome assembly from RNA-Seq data without a reference genome. Nat Biotechnol (2011) 53.86
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood (2003) 20.10
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell (2008) 18.18
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol (2010) 9.01
Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science (2007) 8.07
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Chemically derived, ultrasmooth graphene nanoribbon semiconductors. Science (2008) 7.65
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A (2006) 6.82
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 6.80
In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature (2005) 6.60
Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature (2013) 6.50
Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med (2007) 6.47
Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med (2014) 6.12
Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science (2009) 6.07
Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med (2003) 6.07
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 6.02
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med (2007) 5.87
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol (2009) 5.44
Peroxisomes are signaling platforms for antiviral innate immunity. Cell (2010) 5.24
Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet (2007) 5.16
A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell (2009) 4.98
A glycine-dependent riboswitch that uses cooperative binding to control gene expression. Science (2004) 4.91
Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med (2007) 4.80
Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc Natl Acad Sci U S A (2003) 4.76
Narrow graphene nanoribbons from carbon nanotubes. Nature (2009) 4.66
Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomised controlled equivalence trial. Lancet (2012) 4.51
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood (2006) 4.46
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
New RNA motifs suggest an expanded scope for riboswitches in bacterial genetic control. Proc Natl Acad Sci U S A (2004) 4.35
Toll-like receptors stimulate human neutrophil function. Blood (2003) 4.29
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol (2013) 4.20
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A (2005) 4.15
Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods (2006) 4.12
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol (2003) 4.07
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2004) 3.84
Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med (2011) 3.83
Metabolic labeling of RNA uncovers principles of RNA production and degradation dynamics in mammalian cells. Nat Biotechnol (2011) 3.81
Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell (2011) 3.81
Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci U S A (2010) 3.78
A multigene predictor of outcome in glioblastoma. Neuro Oncol (2009) 3.57
Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med (2013) 3.39
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation (2004) 3.35
The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology (2005) 3.33
The diagnostic accuracy of serologic tests for celiac disease: a systematic review. Gastroenterology (2005) 3.33
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24
Histidines, heart of the hydrogen ion channel from influenza A virus: toward an understanding of conductance and proton selectivity. Proc Natl Acad Sci U S A (2006) 3.22
Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein, hnRNPLL. Science (2008) 3.17
Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature (2016) 3.13
Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res (2005) 3.10
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood (2006) 3.08
N-doping of graphene through electrothermal reactions with ammonia. Science (2009) 3.07
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res (2011) 3.05
A high-throughput chromatin immunoprecipitation approach reveals principles of dynamic gene regulation in mammals. Mol Cell (2012) 3.04
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res (2010) 2.99
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol (2013) 2.94
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A (2003) 2.90
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood (2004) 2.89
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A (2007) 2.87
Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell (2012) 2.84
High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". Circulation (2008) 2.83
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83